All studies showed the superiority of dual GIP/GLP-1RA, GCGR/GLP-1RA or GLP-1RA in decreasing the intrahepatic lipid content in individuals with MASLD and T2D. The gene discussed is GCGR; the disease is metabolic dysfunction-associated steatotic liver disease.